Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch <i>et al</i>.

Chheda, Zinal S; Mueller, Sabine; Hegde, Bindu; Yamamichi, Akane; Butterfield, Lisa H; Okada, Hideho

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al.

Chheda, Zinal S; Mueller, Sabine; Hegde, Bindu; Yamamichi, Akane; Butterfield, Lisa H; Okada, Hideho.

Affiliation

Chheda ZS; Sanofi Genzyme, Cambridge, Massachusetts, USA.
Mueller S; Department of Neurology, UCSF, San Francisco, California, USA.
Hegde B; Department of Neurosurgery, UCSF, San Francisco, California, USA.
Yamamichi A; Department of Pediatrics, UCSF, San Francisco, California, USA.
Butterfield LH; Children's University Hospital, Zurich, Switzerland.
Okada H; 3T Biosciences Inc, Palo Alto, California, USA.

J Immunother Cancer ; 11(3)2023 03.

Article de En | MEDLINE | ID: mdl-36944450

Sujet(s)
Mots clés

Antigens, Neoplasm; Brain Neoplasms; CD8-Positive T-Lymphocytes; Immunotherapy; T-Lymphocytes

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antigène HLA-A2 / Gliome Limites: Humans Langue: En Journal: J Immunother Cancer Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google